Obeticholic Acid Ameliorates Non-Alcoholic Fatty Liver Disease By Improving Metabolic Profile In Dietary Obesity, But Not In Obese, Diabetic Foz/Foz Mice
Date
2016
Authors
Haczeyni, Fahrettin
Poekes, Laurence
Barn, Vanessa
Mridha, Auvro
Haigh, W Geoffrey
Ioannou, George
Yeh, Matthew
Leclercq, Isabelle
Teoh, Narcissus
Farrell, Geoffrey
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V
Abstract
Background and Aims: The semi-synthetic farnesoid X receptor
(FXR) agonist obeticholic acid (OCA) improves steatosis in patients
with non-alcoholic steatohepatitis (NASH), but protective
mechanisms remain unresolved. NASH is the outcome of complex
interactions between nutrient supply, blood glucose, and adipose
lipid storage capacity reflected by adipose morphology and
inflammation. We therefore investigated the effects of OCA on
glucose metabolism, adipose depots and liver in atherogenic dietfed
wildtype (Wt) mice which develop dietary obesity, and Alms1
mutant (foz/foz) hyperphagic mice which develop metabolic obesity
with diabetes.
Description
Keywords
Citation
Collections
Source
Journal of Hepatology
Type
Conference poster
Book Title
Entity type
Access Statement
License Rights
DOI
10.1016/S0168-8278(16)01283-6
Restricted until
2099-12-31